Amal El Beshlawy
Prof. Dr. Pediatric Hematology
(email)
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
View
What links here
Citation:
El-Beshlawy, A., "Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A", haemophilia, vol. 27, issue 4, pp. e441-e449, 2021.
Export
RTF
Tagged
XML
BibTex
Google Scholar
Preview
Attachment
Size
haemophilia_-_2021_-_hassan_-_performance_of_a_clinical_risk_prediction_model_for_inhibitor_formation_in_severe_haemophilia_1.pdf
542.76 KB
Bio
Professor Amal El-Beshlawy CV
Publications
Short CV
Recent Publications
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia.
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Egyptian Gaucher disease type 3 patients: a large cohort study spanning two decades (journal article)
more
Tourism